Ionis Pharmaceuticals Q2 2024 Adj. EPS $(0.24) Beats $(0.92) Estimate, Sales $225.000M Beat $150.073M Estimate
Portfolio Pulse from Benzinga Newsdesk
Ionis Pharmaceuticals reported Q2 2024 adjusted EPS of $(0.24), beating the estimate of $(0.92). Sales were $225 million, surpassing the $150.073 million estimate.
August 01, 2024 | 11:37 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ionis Pharmaceuticals reported better-than-expected Q2 2024 results with an adjusted EPS of $(0.24) compared to the $(0.92) estimate and sales of $225 million versus the $150.073 million estimate.
The significant beat on both EPS and sales estimates is likely to positively impact Ionis Pharmaceuticals' stock price in the short term. Investors typically react favorably to such earnings surprises.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100